CN Patent

CN105732575A — 一种治疗前列腺癌的新型抗雄激素类药物的新晶型及其制备方法

Assigned to Crystal Pharmatech Co Ltd · Expires 2016-07-06 · 10y expired

What this patent protects

本发明涉及一种治疗前列腺癌的抗雄激素类药物的新晶型及其制备方法。本发明提供的晶型具有良好的稳定性，且溶解度、引湿性符合药用要求。该晶型制备方法简单，成本低廉，对未来该药物的优化和开发具有重要价值。

USPTO Abstract

本发明涉及一种治疗前列腺癌的抗雄激素类药物的新晶型及其制备方法。本发明提供的晶型具有良好的稳定性，且溶解度、引湿性符合药用要求。该晶型制备方法简单，成本低廉，对未来该药物的优化和开发具有重要价值。

Drugs covered by this patent

Patent Metadata

Patent number
CN105732575A
Jurisdiction
CN
Classification
—
Expires
2016-07-06
Drug substance claim
No
Drug product claim
No
Assignee
Crystal Pharmatech Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.